Magne Refsnes

Elevated level of β-adrenergic receptors in hepatocytes from regenerating rat liver: Time study of [125I]iodocyanopindolol binding following partial hepatectomy and its relationship to catecholamine-sensitive adenylate cyclase

Hepatocytes from regenerating rat liver show an enhanced epinephrine-sensitive adenylate cyclase activity and cAMP response, which may be involved in triggering of the cell proliferation. We have determined adrenergic receptors and adenylate cyclase activity in hepatocytes isolated at various time points after partial hepatectomy. The number of beta-adrenergic receptors, measured by binding of [125I]iodocyanopindolol ([125I]CYP) to a particulate fraction prepared from isolated hepatocytes, increased rapidly after partial hepatectomy as compared with sham-operated or untreated controls. The maximal increase, which was observed at 48 h, was between 5- and 6-fold (from approximately 1 800 to approximately 10 500 sites per cell). Thereafter, the number of beta-adrenergic receptors decreased gradually. Competition experiments indicated beta 2-type receptors. Parallelism was found between the change in the number of beta 2-adrenergic receptors and the isoproterenol-responsive adenylate cyclase activity. The number of alpha 1-adrenergic receptors, determined by binding of [3H]prazosin, was transiently lowered by about 35% at 18-24 h, with no significant change in Kd. Although the results of this study do not exclude the possibility of post-receptor events, they suggest that the increased number of beta 2-adrenergic receptors is a major factor responsible for the enhanced catecholamine-responsive adenylate cyclase activity in regenerating liver.

Mechanisms for the emergence of catecholamine-sensitive adenylate cyclase and β-adrenergic receptors in cultured hepatocytes: Dependence on protein and RNA synthesis and suppression by isoproterenol

Adult male rat hepatocytes, which normally respond poorly to β‐adrenergic agents, acquire such responsiveness during primary monolayer culture. We here show that the rise in catecholamine‐sensitive adenylate cyclase activity in hepatocytes in vitro is closely paralleled by an increase in the ability to bind the β‐adrenoceptor ligand [125I]cyanopindolol. The emergence of β‐adrenergic responsiveness did not require cell attachment or serum. Addition of dexamethasone, insulin, thyroxine or dihydortestosterone to the cultures, singly or in combination, did not prevent the augmented β‐adrenergic responsiveness. The increase in catecholamine‐sensitive adenylate cyclase activity and [125I]cyanopindolol binding could be blocked by cycloheximide or actinomycin D. Exposure of the cultures to isoproterenol at 3‐hourly intervals led to a dose‐dependent suppression of the rise in isoproterenol‐responsive adenylate cyclase and prevented the increase in β‐adrenoceptor binding.Adult male rat hepatocytes, which normally respond poorly to beta-adrenergic agents, acquire such responsiveness during primary monolayer culture. We here show that the rise in catecholamine-sensitive adenylate cyclase activity in hepatocytes in vitro is closely paralleled by an increase in the ability to bind the beta-adrenoceptor ligand [125I]cyanopindolol. The emergence of beta-adrenergic responsiveness did not require cell attachment or serum. Addition of dexamethasone, insulin, thyroxine or dihydrotestosterone to the cultures, singly or in combination, did not prevent the augmented beta-adrenergic responsiveness. The increase in catecholamine-sensitive adenylate cyclase activity and [125I]cyanopindolol binding could be blocked by cycloheximide or actinomycin D. Exposure of the cultures to isoproterenol at 3-hourly intervals led to a dose-dependent suppression of the rise in isoproterenol-responsive adenylate cyclase and prevented the increase in beta-adrenoceptor binding.

Growth‐promoting effects of Ca2+‐mobilizing agents in hepatocytes: Lack of correlation between the acute activation of phosphoinositide‐specific phospholipase C and the stimulation of DNA synthesis by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2α

Although several hormones that promote hepatocyte proliferation also activate phosphoinositide‐specific phospholipase C (PI‐PLC) and mobilize Ca2+, the role of PI‐PLC in the growth‐stimulating effect of these agents is not clear. We have investigated this issue further, by exposing freshly isolated adult rat hepatocytes to vasopressin, angiotensin II, norepinephrine (in the presence of the β‐adrenoceptor blocker timolol) or PGF2α, and examined both acute responses and the subsequent DNA synthesis when the cells were grown in monolayer culture. All the agonists elevated the level of inositol 1,4,5‐trisphosphate (InsP3) and enhanced the DNA synthesis, amplifying the response to epidermal growth factor (EGF), and this comitogenic effect could be exerted by a single exposure of the cells 24 h prior to the addition of EGF. The acute activation of PI‐PLC, measured as the early rise (peak 15–60 s) in InsP3, was 8–10‐fold with vasopressin or angiotensin II, 3–4‐fold with norepinephrine, and ∼︁2‐fold with PGF2α. For all the agonists, a rise in cytosolic free Ca2+ in 100% of the cells and a maximal increase in glycogen phosphorylase activity were evoked at concentrations that approximately doubled the level of InsP3. However, the growth‐stimulatory effects of these agonists showed a different order of efficacy as compared to the activation of PI‐PLC; in terms of the maximal stimulation of DNA synthesis, the effects were: norepinephrine ≈︂ PGF2α > angiotensin II > vasopressin. Also, norepinephrine, PGF2α, and angiotensin II, but not vasopressin, further enhanced the DNA synthesis when their concentrations were increased above those yielding maximal elevation of InsP3. In experiments where vasopressin and angiotensin II were combined, their effects on the DNA synthesis were additive while the InsP3 responses were not. The results show that the extent of the initial activation of PI‐PLC is not the determinant for the magnitude of the growth effects of Ca2+‐mobilizing hormones in hepatocytes. This suggests either (a) that the proliferative response to these agents is determined by the activity of PI‐PLC at a later time, or its integral over an extended part of the prereplicative period, rather than by the acute activation, or (b) that additional, PI‐PLC‐independent, mechanisms are required.

Growth-regulatory effects of glucagon, insulin, and epidermal growth factor in cultured hepatocytes : temporal aspects and evidence for bidirectional control by cyclic AMP

Data presented indicate that in hepatocytes insulin and glucagon promote growth by acting in a relatively early part of the prereplicative period (G0 or early G1) whereas cells (if pretreated with insulin) become more sensitive to EGF at the later stages, ie, nearer the S phase entry. The data indicate that at least two effects of glucagon (cAMP) on hepatocyte proliferation exist; in addition to a growth-promoting modulation early in the prereplicative period, there is also an inhibitory effect of glucagon (as well as other cAMP-elevating agents) that is exerted at a point shortly before the G1-to-S transition. Because both effects occur dose-dependently in the normal range of glucagon concentrations in portal blood, it is conceivable that glucagon/cAMP is involved both when liver growth is initiated and terminated.

Regulation of surface expression of high-affinity receptors for epidermal growth factor (EGF) in hepatocytes by hormones, differentiating agents, and phorbol ester

Freshly isolated adult rat hepatocytes exhibit a nonhomogeneous population of epidermal growth factor (EGF) receptors with about 10,000 high-affinity binding sites (Kd 20 pM) and about 200,000 low-affinity sites (Kd 600 pM) per cell. With culturing as primary monolayers under conditions where the cells show a marked increase in the sensitivity to the growth-stimulatory effect of EGF, a gradual reduction in the number of EGF receptors and an almost complete loss of high-affinity EGF receptors is seen. Insulin, which promotes growth of hepatocytes in concert with EGF, enhances the down-regulation of these high-affinity receptors. The differentiating (and growth-inhibitory) agentn-butyrate counteracts this down-regulation and preserves the high-affinity receptors. This effect of butyrate is synergistic with the glucocorticoid agent dexamethasone. Another differentiating agent, dimethylsulfoxide (DMSO), also counteracts the down-regulation of high-affinity EGF receptors. Moreover, the tumor promoter, tetradecanoylphorbol acetate (TPA), down-regulates the EGF receptor. This effect is particularly evident when studying the high-affinity receptors up-regulated by prior treatment with butyrate plus dexamethyasone. Taken together these results provide strong support for the notion that an inverse relationship exists between expression of high-affinity EGF binding and responsiveness to growth activation by EGF.

Down-regulation of surface beta-adrenoceptors on intact human mononuclear leukocytes: Time-course and isoproterenol concentration dependence

Incubation of human mononuclear leukocytes (MNL) in vitro with isoproterenol resulted in a rapid loss of surface beta-adrenoceptors, determined by radioligand binding at 4 degrees. Isoproterenol concentrations in the range of 10 nM to 100 microM resulted in significant down-regulation of beta-adrenoceptors. At a concentration of 1 microM isoproterenol, the time-dependent loss of surface beta-adrenoceptors closely paralleled the loss in isoproterenol-stimulated adenylate cyclase activity. If receptor number in intact cells was determined at 32 degrees, hardly any loss in receptor number was observed, due to reversal of down-regulation during the incubation period. When beta-adrenoceptor number in broken cell preparations was determined by [125I]cyanopindolol binding at 37 degrees no significant loss was observed, even after 2 hr of isoproterenol treatment, while [3H]CGP-12177 binding resulted in a similar reduction in binding sites as in intact cells. Reversal of loss in surface beta-adrenoceptors was rapid after 1 hr pretreatment with isoproterenol, but followed a biphasic time course after 4 hr pretreatment, with an initial rapid return of about 40% of the down-regulated receptors, followed by a slow, gradual reappearance of receptors. The results indicate that catecholamine exposure leads to a rapid sequestration of MNL surface beta-adrenoceptors away from the cell surface, to a compartment where they are inaccessible to the hydrophilic ligand [3H]CGP-12177 as well as to the lipophilic ligand [125I]cyanopindolol at 4 degrees. Up to 2 hr of isoproterenol treatment does not lead to any breakdown of sequestered beta-adrenoceptors, as they are still recognized by [125I]cyanopindolol binding in broken cell preparations.

Mechanisms of hepatocyte growth regulation by hormones and growth factors

The striking ability of mature, quiescent liver cells to rapidly reenter the cell cycle and proliferate to compensate for loss or injury of hepatic tissue has long fascinated scientists [1–3]. Evidence from in vivo experiments, dating back from early, pioneering work [4–9], strongly suggested that hepatic growth is under humoral control. The development of techniques for hepatocyte isolation [10,11] has permitted the study of hepatocyte growth in culture. This has contributed greatly to identifying agents and mechanisms that initiate, sustain, and terminate liver cell proliferation.

Growth Stimulation Mediated by G Protein Coupled Receptors in Hepatocytes: Synergism with Epidermal Growth Factor and Mechanisms of Signal Transduction

Hepatocyte proliferation is stimulated not only by mitogenic growth factors through tyrosine kinase receptors, but also by a number of other hormonal agents, most of which exert their effects via G protein-coupled receptors. Although factors in the latter category usually seem to act permissively rather than as complete, independent, hepatic mitogens, the magnitude of their effects may under optimal conditions be quite substantial. A more precise understanding of how their signals are mediated and integrated with the actions of mitogenic growth factors in hepatocytes may yield insights into mechanisms of both hepatic and general growth regulation.

Long-term inhibitory effect of cAMP on β-adrenoceptor acquisition and nonselective attenuation of adenylyl cyclase in hepatocytes

Long-term effects of cAMP on the surface expression of beta-adrenoceptors and adenylyl cyclase activity were investigated in primary cultures of rat hepatocytes. beta-Adrenoceptor density and catecholamine-responsive adenylyl cyclase activity increased during culturing in a biphasic manner, with a plateau of 10-20 h duration occurring approximately 10 h after plating. Treatment of hepatocyte cultures with 8-bromo-cAMP during the plateau period did not affect the density of beta-adrenoceptors. In contrast, addition of 8-bromo-cAMP, 8-chlorophenylthio-cAMP, forskolin or glucagon during a period of active recruitment of surface beta-adrenoceptors resulted in a suppression of the acquisition of beta-adrenoceptors. In both experimental situations there was a partial decrease in hormone-stimulated and basal adenylyl cyclase activity. The results suggest that cAMP exerts at least two types of long-term regulation of adenylyl cyclase in hepatocytes: a suppressive effect on beta-adrenoceptor acquisition, and a partial, nonselective decrease in adenylyl cyclase activity not involving beta-adrenoceptor down-regulation.